CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net loss	$ (338,844)	$ (587,756)	$ (136,392)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	1,187	1,246	555
Amortization of notes and securities discounts and debt issuance costs	30	13,717	21,118
Stock-based compensation expense	164,305	163,723	7,078
Paid-in-kind interest	0	0	28,334
Change in fair value of warrants and amortization of warrants	(900)	(66,146)	80,328
Change in derivative liabilities	0	0	(93,751)
Accretion, net of amortization	(1,503)	200	(195)
Net realized losses on investment securities	267	53	(1,114)
Gain on extinguishment of note payable	(23,326)	0	0
Gain on investment	(9,217)	0	0
Premium deficiency reserve	(94,240)	110,628	(17,128)
Changes in operating assets and liabilities:
Accrued retrospective premiums	14,536	(94)	(21,604)
Other receivables	(8,988)	(2,914)	(5,865)
Reinsurance recoverable	0	(96)	481
Surety bonds and deposits	(7,424)	(10,656)	0
Prepaid expenses	(3,415)	(6,863)	(6,473)
Other assets	(1,204)	(4,296)	1,003
Healthcare receivables	(22,565)	(9,297)	(12,926)
Non-Insurance receivable	(40,785)	(12,170)	0
Operating lease right-of-use assets	1,984	3,591	3,257
Unpaid claims	2,589	36,948	26,090
Accounts payable and accrued expenses	7,635	5,307	10,845
Accrued salaries and benefits	8,784	11,169	186
Deferred rent	0	68	0
Other liabilities	2,468	979	1,378
Performance year obligation	36,953	36,891
Non-Insurance payable	110,418	37,773	0
Operating lease liabilities	(2,671)	(4,331)	(3,703)
Net cash used in operating activities	(203,926)	(282,326)	(118,498)
Cash flows from investing activities:
Purchases of short-term investments, available-for-sale, and held-to-maturity securities	(369,396)	(876,252)	(174,318)
Proceeds from sales of short-term investments and available-for-sale securities	13,348	126,862	248,664
Proceeds from maturities of short-term investments, available-for-sale, and held-to-maturity securities	472,098	314,666	63,751
Acquisition of business, net of cash acquired	(16,200)	0	0
Purchases of property and equipment	(4,467)	(723)	(693)
Acquisition of Character Biosciences, Inc. Series A preferred shares	(250)	0	0
Net cash provided by (used in) investing activities	95,133	(435,447)	137,404
Cash flows from financing activities:
Proceeds from issuance of convertible notes	0	0	20,000
Deferred financing costs	0	0	(98)
Payment of notes payable principal	0	(30,925)	(18,752)
Issuance of common stock, net of early exercise liability	1,400	6,144	1,748
Proceeds from reverse recapitalization, net of transaction costs	0	666,241	0
Buyback and subsequent cancellation of common shares	0	0	(957)
Proceeds received for the exercise of public and private warrants	0	390	0
Issuance of common stock, net of stock issuance costs	0	283,775	0
Payment for the redemptions of public warrants	0	(85)	0
Treasury stock acquired	(6,362)	(147)	0
Acquisition of noncontrolling interest	0	0	3,903
Net cash (used in) provided by financing activities	(4,962)	925,393	5,844
Net (decrease) increase in cash, cash equivalents, and restricted cash	(113,755)	207,620	24,750
Cash, cash equivalents, and restricted cash, beginning of period	299,968	92,348	67,598
Cash, cash equivalents, and restricted cash , end of period	186,213	299,968	92,348
Reconciliation of cash and cash equivalents and restricted cash
Cash and cash equivalents	103,791	299,968	92,348
Restricted cash	82,422	0	0
Total cash, cash equivalents, and restricted cash	186,213	299,968	92,348
Supplemental cash flow disclosures
Cash paid during the period for interest	0	1,677	4,578
Cash paid during the year for health insurance industry fee	0	0	8,022
Supplemental disclosure of non-cash activities
Conversion of preferred stock to common stock	0	447,747	0
Issuance of common stock related to convertible debt	0	16,059	0
Capital contribution for extinguishment of debt	0	126,795	0
Activities from Seek Dissolution	735	0	0
Issuance of common stock related to warrants exercised	0	97,782	0
Acquisition of public and private warrants	0	147,582	0
Issuance of common stock related to the exercise of public and private warrants	0	81,283	0
Right-of-use assets obtained in exchange for lease liabilities	642	1,076	42
Recognition of equity method investments and preferred stock	8,644	0	0
Derecognition of noncontrolling interest	3,903	0	0
Conversion of Character Biosciences, Inc. convertible note to preferred stock	$ 250	$ 0	$ 0